---
document_datetime: 2025-12-02 05:00:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/penbraya.html
document_name: penbraya.html
version: success
processing_time: 0.1113212
conversion_datetime: 2025-12-24 02:27:05.307079
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Penbraya

[RSS](/en/individual-human-medicine.xml/249350)

##### Withdrawn

This medicine's authorisation has been withdrawn

meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed) Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Penbraya](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 20 January 2025, the European Commission withdrew the marketing authorisation for Penbraya (meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed)) in the European Union (EU).

The withdrawal was at the request of the marketing authorisation holder, Pfizer Europe MA EEIG, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Penbraya was granted marketing authorisation in the EU on 14 November 2024 for the \"active immunisation of individuals 10 years of age and older to prevent invasive disease caused by Neisseria meningitidis groups A, B, C, W, and Y. The use of this vaccine should be in accordance with official recommendations.\" The marketing authorisation was initially valid for a 5-year period.

The European Public Assessment Report (EPAR) for Penbraya is updated to indicate that the marketing authorisation is no longer valid.

Penbraya : EPAR - Medicine overview

Reference Number: EMEA/H/C/006165

English (EN) (211.02 KB - PDF)

**First published:** 12/12/2024

**Last updated:** 05/02/2025

[View](/en/documents/overview/penbraya-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-22)

български (BG) (279.79 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/bg/documents/overview/penbraya-epar-medicine-overview_bg.pdf)

español (ES) (210.36 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/es/documents/overview/penbraya-epar-medicine-overview_es.pdf)

čeština (CS) (265.93 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/cs/documents/overview/penbraya-epar-medicine-overview_cs.pdf)

dansk (DA) (206.47 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/da/documents/overview/penbraya-epar-medicine-overview_da.pdf)

Deutsch (DE) (221.41 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/de/documents/overview/penbraya-epar-medicine-overview_de.pdf)

eesti keel (ET) (199.41 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/et/documents/overview/penbraya-epar-medicine-overview_et.pdf)

ελληνικά (EL) (291.38 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/el/documents/overview/penbraya-epar-medicine-overview_el.pdf)

français (FR) (214.43 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/fr/documents/overview/penbraya-epar-medicine-overview_fr.pdf)

hrvatski (HR) (240.13 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/hr/documents/overview/penbraya-epar-medicine-overview_hr.pdf)

italiano (IT) (206.93 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/it/documents/overview/penbraya-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (245.7 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/lv/documents/overview/penbraya-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (256.03 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/lt/documents/overview/penbraya-epar-medicine-overview_lt.pdf)

magyar (HU) (254.38 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/hu/documents/overview/penbraya-epar-medicine-overview_hu.pdf)

Malti (MT) (258.77 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/mt/documents/overview/penbraya-epar-medicine-overview_mt.pdf)

Nederlands (NL) (221.54 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/nl/documents/overview/penbraya-epar-medicine-overview_nl.pdf)

polski (PL) (261.3 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/pl/documents/overview/penbraya-epar-medicine-overview_pl.pdf)

português (PT) (209.83 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/pt/documents/overview/penbraya-epar-medicine-overview_pt.pdf)

română (RO) (256.29 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/ro/documents/overview/penbraya-epar-medicine-overview_ro.pdf)

slovenčina (SK) (275.45 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/sk/documents/overview/penbraya-epar-medicine-overview_sk.pdf)

slovenščina (SL) (241.56 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/sl/documents/overview/penbraya-epar-medicine-overview_sl.pdf)

Suomi (FI) (202.59 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/fi/documents/overview/penbraya-epar-medicine-overview_fi.pdf)

svenska (SV) (201.16 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/sv/documents/overview/penbraya-epar-medicine-overview_sv.pdf)

Penbraya :  EPAR - Risk-management-plan

English (EN) (3.29 MB - PDF)

**First published:** 12/12/2024

**Last updated:** 05/02/2025

[View](/en/documents/rmp/penbraya-epar-risk-management-plan_en.pdf)

## Product information

Penbraya : EPAR - Product information

English (EN) (1.36 MB - PDF)

**First published:** 12/12/2024

**Last updated:** 05/02/2025

[View](/en/documents/product-information/penbraya-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-144)

български (BG) (1.73 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/bg/documents/product-information/penbraya-epar-product-information_bg.pdf)

español (ES) (1.72 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/es/documents/product-information/penbraya-epar-product-information_es.pdf)

čeština (CS) (1.72 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/cs/documents/product-information/penbraya-epar-product-information_cs.pdf)

dansk (DA) (1.68 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/da/documents/product-information/penbraya-epar-product-information_da.pdf)

Deutsch (DE) (1.73 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/de/documents/product-information/penbraya-epar-product-information_de.pdf)

eesti keel (ET) (1.71 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/et/documents/product-information/penbraya-epar-product-information_et.pdf)

ελληνικά (EL) (1.75 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/el/documents/product-information/penbraya-epar-product-information_el.pdf)

français (FR) (1.55 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/fr/documents/product-information/penbraya-epar-product-information_fr.pdf)

hrvatski (HR) (1.57 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/hr/documents/product-information/penbraya-epar-product-information_hr.pdf)

íslenska (IS) (1.5 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/is/documents/product-information/penbraya-epar-product-information_is.pdf)

italiano (IT) (1.69 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/it/documents/product-information/penbraya-epar-product-information_it.pdf)

latviešu valoda (LV) (1.69 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/lv/documents/product-information/penbraya-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.49 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/lt/documents/product-information/penbraya-epar-product-information_lt.pdf)

magyar (HU) (1.74 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/hu/documents/product-information/penbraya-epar-product-information_hu.pdf)

Malti (MT) (1.88 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/mt/documents/product-information/penbraya-epar-product-information_mt.pdf)

Nederlands (NL) (1.76 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/nl/documents/product-information/penbraya-epar-product-information_nl.pdf)

norsk (NO) (1.59 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/no/documents/product-information/penbraya-epar-product-information_no.pdf)

polski (PL) (1.76 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/pl/documents/product-information/penbraya-epar-product-information_pl.pdf)

português (PT) (1.7 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/pt/documents/product-information/penbraya-epar-product-information_pt.pdf)

română (RO) (1.74 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/ro/documents/product-information/penbraya-epar-product-information_ro.pdf)

slovenčina (SK) (1.78 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/sk/documents/product-information/penbraya-epar-product-information_sk.pdf)

slovenščina (SL) (1.7 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/sl/documents/product-information/penbraya-epar-product-information_sl.pdf)

Suomi (FI) (1.79 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/fi/documents/product-information/penbraya-epar-product-information_fi.pdf)

svenska (SV) (1.69 MB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/sv/documents/product-information/penbraya-epar-product-information_sv.pdf)

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Penbraya : EPAR - All authorised presentations

English (EN) (94.32 KB - PDF)

**First published:** 12/12/2024

**Last updated:** 05/02/2025

[View](/en/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-722)

български (BG) (106.44 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/bg/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_bg.pdf)

español (ES) (98.67 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/es/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_es.pdf)

čeština (CS) (97.2 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/cs/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (86.3 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/da/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (98.69 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/de/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (95.79 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/et/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (100.96 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/el/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_el.pdf)

français (FR) (95.49 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/fr/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (109.04 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/hr/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (94.99 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/is/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_is.pdf)

italiano (IT) (96.11 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/it/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (97.84 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/lv/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (97.46 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/lt/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (96.29 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/hu/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (104.95 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/mt/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (102.31 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/nl/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (93.14 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/no/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_no.pdf)

polski (PL) (89.93 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/pl/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_pl.pdf)

português (PT) (110.91 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/pt/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_pt.pdf)

română (RO) (94.64 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/ro/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (100.04 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/sk/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (85.44 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/sl/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (100.7 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/fi/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (95.37 KB - PDF)

**First published:**

12/12/2024

**Last updated:**

05/02/2025

[View](/sv/documents/all-authorised-presentations/penbraya-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Penbraya Active substance

- Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid
- Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid
- Neisseria meningitidis group W polysaccharide conjugated to tetanus toxoid
- Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid
- Neisseria meningitidis group B fHBP protein subfamily A
- Neisseria meningitidis group B fHBP protein subfamily B

International non-proprietary name (INN) or common name meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed) Therapeutic area (MeSH) Meningitis, Meningococcal Anatomical therapeutic chemical (ATC) code J07AH11

### Pharmacotherapeutic group

Vaccines, meningococcal vaccines

### Therapeutic indication

Penbraya is indicated for active immunisation of individuals 10 years of age and older to prevent invasive disease caused by *Neisseria meningitidis* groups A, B, C, W, and Y.

The use of this vaccine should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/006165 Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 19/09/2024 Marketing authorisation issued 14/11/2024 Withdrawal of marketing authorisation 20/01/2025

## Assessment history

## Initial marketing authorisation documents

Penbraya : EPAR - Public assessment report

Reference Number: EMA/464092/2024

English (EN) (8.56 MB - PDF)

**First published:** 12/12/2024

**Last updated:** 05/02/2025

[View](/en/documents/assessment-report/penbraya-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Penbraya

Adopted

Reference Number: EMA/424272/2024

English (EN) (182.68 KB - PDF)

**First published:** 20/09/2024

**Last updated:** 05/02/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-penbraya_en.pdf)

#### News on Penbraya

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2024) 20/09/2024

**This page was last updated on** 05/02/2025

## Share this page

[Back to top](#main-content)